QNDPF yields 5.59% · JNJ yields 2.13%● Live data
📍 QNDPF pulled ahead of the other in Year 1
Combined, QNDPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QNDPF + JNJ for your $10,000?
Qingdao Port International Co., Ltd. operates the Port of Qingdao. It operates through six segments: Container Handling and Ancillary Services; Metal Ores, Coal and Other Cargo Handling and Ancillary Services; Liquid Bulk Handling and Ancillary Services; Logistics and Port Value-Added Services; Port Ancillary Services; and Financial Services. The company is involved in the loading and discharging of containers, metal ores, coal, grains, and break bulk and liquid bulk cargos, as well as other general cargos. It also provides storage services; and port management, container freight station, cargo logistics, agency, towing, tallying, facilities construction, and other services. In addition, the company manufactures port related equipment; and supplies electricity power, fuel, and other products. Further, it offers port machinery manufacture, construction, tugboat and barging, and ocean shipping tallying services; and security, emergency, stevedoring and handling, and textile and apparel services. Additionally, the company provides financial products and services comprising deposit taking, guarantee, insurance agency, and investment and financial management services, as well as corporate loans; and shipping repair and agency, engineering and construction, cargo and trade agency, engineering design, technology, property management, media, lightering, oil pipeline transportation, and check and inspection services. It also engages in the LNG operations. As of December 31, 2021, it operated 92 berths at the Port of Qingdao. The company was incorporated in 2013 and is headquartered in Qingdao, the People's Republic of China. Qingdao Port International Co., Ltd. operates as a subsidiary of Shandong Qingdao Port Group Co., Ltd.
Full QNDPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.